Everence Capital Management Inc. trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5 ...
This was the stock's third consecutive day of gains.
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
Vertex Pharmaceuticals (VRTX) closed the latest trading day at $402.70, indicating a +0.84% change from the previous session's end. This change outpaced the S&P 500's 0.43% loss on the day. At the ...
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...